Scarica l'app Stockscreener
3.52
3.83%
-0.14
Pre-mercato:
3.52
Precedente Chiudi:
$3.66
Aprire:
$3.66
Volume 24 ore:
1.63M
Relative Volume:
0.66
Capitalizzazione di mercato:
$579.44M
Reddito:
$361.51M
Utile/perdita netta:
$102.18M
Rapporto P/E:
5.8922
EPS:
0.5974
Flusso di cassa netto:
$112.21M
1 W Prestazione:
+5.07%
1M Prestazione:
-1.68%
6M Prestazione:
+4.45%
1 anno Prestazione:
+454.68%
Intervallo 1D:
$3.51
$3.72
Intervallo di 1 settimana:
$3.33
$3.79
Portata 52W:
$0.62
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Nome
Ironwood Pharmaceuticals Inc
Settore
Telefono
617-621-7722
Indirizzo
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.52 | 607.42M | 361.51M | 102.18M | 112.21M | 0.5974 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | Downgrade | Jefferies | Buy → Hold |
| 2025-04-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | Iniziato | Leerink Partners | Market Perform |
| 2024-08-08 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Wells Fargo | Overweight |
| 2023-11-09 | Iniziato | Jefferies | Buy |
| 2023-09-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-02 | Iniziato | CapitalOne | Overweight |
| 2022-04-22 | Iniziato | Piper Sandler | Overweight |
| 2020-09-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | Iniziato | Northland Capital | Outperform |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2018-11-07 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-07-23 | Iniziato | H.C. Wainwright | Sell |
| 2018-05-09 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | Downgrade | Mizuho | Buy → Neutral |
| 2017-07-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2017-05-03 | Iniziato | Wells Fargo | Outperform |
| 2017-04-07 | Reiterato | Mizuho | Buy |
| 2017-02-22 | Reiterato | Barclays | Equal Weight |
| 2016-11-04 | Reiterato | Mizuho | Buy |
| 2016-10-24 | Reiterato | Wedbush | Neutral |
| 2016-10-10 | Reiterato | Mizuho | Buy |
| 2016-09-27 | Reiterato | WallachBeth | Hold |
Mostra tutto
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Ironwood Pharmaceuticals (IRWD) Jefferies London Healthcare Conference 2024 Summary - Quartr
Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026 - TradingView
Ironwood Pharmaceuticals (IRWD) retires $200M 2026 convertible notes in cash - Stock Titan
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates - MSN
Ironwood Pharmaceuticals (IRWD) Tops Healthcare Sector with Stro - GuruFocus
These healthcare stocks are combining strong gains with reasonable prices (XLV:NYSEARCA) - Seeking Alpha
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026? - Yahoo Finance
· SEC Filing - MLQ.ai
IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Chart - ChartMill
IRWD: Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead - TradingView
Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026 - The Globe and Mail
Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price, News, Quote & History - Yahoo Finance
Ironwood Pharmaceuticals Expands Linzess Use and Drives Record Q1 2026 Revenue - asatunews.co.id
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess? - Insider Monkey
Ironwood (IRWD) Q1 2026 Earnings Call Transcript - The Globe and Mail
Earnings Preview: IRWD to Report Financial Results Pre-market on May 07 - Moomoo
Ironwood reiterates 2026 LINZESS guidance of $1.125B-$1.175B as STARS-2 initiation nears - MSN
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2026 - BioSpace
Ironwood Pharmaceuticals to Present at Jefferies Global Healthcare Conference - geneonline.com
Ironwood Pharmaceuticals, Inc. (IRWD) stock price, news, quote and history - Yahoo Finance UK
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - investor.ironwoodpharma.com
Ironwood Pharmaceuticals (IRWD) Gains FDA Approval for Linzess i - GuruFocus
FDA approves Linzess for children ages 2-5 with constipation - Investing.com UK
Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation - Seeking Alpha
FDA approves constipation drug LINZESS for kids as young as 2 - Stock Titan
Ironwood Pharmaceuticals (IRWD) Receives Strong Buy Rating Follo - GuruFocus
Ironwood Pharmaceuticals (IRWD) Earns Strong Buy Rating from Qua - GuruFocus
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant - Stock Titan
Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant - Stock Titan
Kyverna Therapeutics appoints Greg Martini as CFO - MSN
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement? - Insider Monkey
Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04 - MSN
Kyverna Therapeutics Appoints Greg Martini CFO Ahead of Potential Commercial Launch - citybiz
Top Small-Cap Stocks to Watch: Ironwood Pharmaceuticals (IRWD) L - GuruFocus
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - GlobeNewswire
Ironwood Pharma drops after CFO transition - MSN
Ironwood Pharmaceuticals: Still A Profitable Opportunity (NASDAQ:IRWD) - Seeking Alpha
Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A - Stock Titan
Ironwood Pharmaceuticals, Inc.Class A Common Stock (NQ: IRWD - FinancialContent
Renaissance reports 4.90% stake in Ironwood (IRWD) - Stock Titan
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating - Moomoo
Ironwood Pharma Announces CFO Resignation and Interim Successor - The Globe and Mail
Ironwood Pharmaceuticals Inc Azioni (IRWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ironwood Pharmaceuticals Inc Azioni (IRWD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| DENNER ALEXANDER J | Director |
Mar 17 '26 |
Sale |
3.05 |
6,730,800 |
20,530,448 |
9,188,635 |
| John Minardo | Chief Legal Officer |
Feb 24 '26 |
Sale |
3.66 |
19,053 |
69,734 |
363,886 |
| John Minardo | Chief Legal Officer |
Feb 23 '26 |
Sale |
3.81 |
17,439 |
66,443 |
382,939 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 23 '26 |
Sale |
3.81 |
15,570 |
59,322 |
538,437 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,287 |
39,193 |
224,977 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 23 '26 |
Sale |
3.81 |
94,757 |
361,024 |
1,592,528 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| Martini Gregory S. | Chief Financial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,487 |
39,955 |
172,058 |
0.95%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):